Treatment of hepatitis C virus with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha 2A/2B and ribavirin
US8664273B2 · kind B2 · utility
0Cited by
0References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 3, 2011 |
| Grant date | Mar 4, 2014 |
| Priority date | — |
| Expiry date | Jun 3, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.